SI2723771T1 - Proteini, ki vežejo serum albumin - Google Patents
Proteini, ki vežejo serum albuminInfo
- Publication number
- SI2723771T1 SI2723771T1 SI201231696T SI201231696T SI2723771T1 SI 2723771 T1 SI2723771 T1 SI 2723771T1 SI 201231696 T SI201231696 T SI 201231696T SI 201231696 T SI201231696 T SI 201231696T SI 2723771 T1 SI2723771 T1 SI 2723771T1
- Authority
- SI
- Slovenia
- Prior art keywords
- serum albumin
- binding proteins
- albumin binding
- proteins
- serum
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500464P | 2011-06-23 | 2011-06-23 | |
| PCT/EP2012/061304 WO2012175400A1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
| EP12727658.2A EP2723771B1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2723771T1 true SI2723771T1 (sl) | 2019-12-31 |
Family
ID=46298413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231696T SI2723771T1 (sl) | 2011-06-23 | 2012-06-14 | Proteini, ki vežejo serum albumin |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9573992B2 (enExample) |
| EP (3) | EP2723771B1 (enExample) |
| JP (3) | JP6324887B2 (enExample) |
| CN (2) | CN106046168A (enExample) |
| AU (1) | AU2012271974B2 (enExample) |
| CA (1) | CA2839779C (enExample) |
| CY (1) | CY1122691T1 (enExample) |
| DK (1) | DK2723771T3 (enExample) |
| ES (1) | ES2759936T3 (enExample) |
| HR (2) | HRP20192160T1 (enExample) |
| HU (1) | HUE047238T2 (enExample) |
| IN (1) | IN2014CN00414A (enExample) |
| LT (1) | LT2723771T (enExample) |
| PL (1) | PL2723771T3 (enExample) |
| PT (1) | PT2723771T (enExample) |
| SI (1) | SI2723771T1 (enExample) |
| WO (1) | WO2012175400A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723771B1 (en) * | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| NZ780183A (en) * | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2747783B1 (en) * | 2011-09-30 | 2017-06-14 | Ablynx N.V. | Biological materials related to c-met |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| EP3143403B1 (en) | 2014-05-16 | 2021-10-27 | Ablynx N.V. | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| PT3248986T (pt) | 2014-05-16 | 2022-04-05 | Ablynx Nv | Domínios variáveis de imunoglobulina |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| JP6862343B2 (ja) | 2014-12-19 | 2021-04-21 | アブリンクス エン．ヴェー． | システイン結合ナノボディダイマー |
| SG11201705986QA (en) | 2015-01-29 | 2017-08-30 | Technophage Investigação E Desenvolvimento Em Biotecnologia Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| NO2768984T3 (enExample) | 2015-11-12 | 2018-06-09 | ||
| EP3974449A1 (en) | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
| CN109071639B (zh) | 2015-11-18 | 2022-07-08 | 默沙东公司 | Pd1/ctla4结合剂 |
| CN120535622A (zh) * | 2015-11-18 | 2025-08-26 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合剂 |
| HK1254952A1 (zh) | 2015-11-18 | 2019-08-02 | Merck Sharp & Dohme Llc | Ctla4结合剂 |
| SG10201911035QA (en) | 2015-11-18 | 2020-01-30 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| CA3006398A1 (en) * | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| BR112018073739A2 (pt) * | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| CA3029133C (en) | 2016-06-23 | 2024-04-30 | Ablynx N.V. | Improved pharmacokinetic assays for immunoglobulin single variable domains |
| AU2017361846B2 (en) | 2016-11-16 | 2024-08-22 | Ablynx Nv | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| CN117164710A (zh) | 2016-12-07 | 2023-12-05 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合免疫球蛋白单可变结构域 |
| CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| ES2991459T3 (es) * | 2017-01-17 | 2024-12-03 | Ablynx Nv | Ligantes de albúmina sérica mejorados |
| SG10202108973SA (en) | 2017-01-17 | 2021-09-29 | Ablynx Nv | Improved serum albumin binders |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| AU2018241286B2 (en) | 2017-03-31 | 2025-03-13 | Ablynx N.V. | Improved immunogenicity assays |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| AR114269A1 (es) * | 2018-02-26 | 2020-08-12 | Ablynx Nv | Secuencias nucleotídicas mejoradas que codifican para péptidos de unión |
| WO2019222283A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| CN110964107B (zh) * | 2018-09-30 | 2022-08-09 | 苏州康宁杰瑞生物科技有限公司 | Met结合分子、其组合和用途 |
| CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
| CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
| US20220227850A1 (en) * | 2019-05-15 | 2022-07-21 | Crescendo Biologics Limited | Binding molecules |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CA3163764A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l |
| CN114981300B (zh) | 2019-12-06 | 2025-10-31 | 艾伯霖克斯公司 | 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽 |
| AU2020400938A1 (en) | 2019-12-09 | 2022-07-28 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP |
| CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| EP4126971A1 (en) | 2020-03-30 | 2023-02-08 | Ablynx N.V. | Method for the production and purification of multivalent immunoglobulin single variable domains |
| CA3195687A1 (en) | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| CN112142846B (zh) * | 2020-10-10 | 2022-07-08 | 西北大学 | Aox特异性抗体组合及其制备方法和用途 |
| CN115244076B (zh) * | 2020-10-27 | 2023-08-04 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
| JP2023549537A (ja) * | 2020-11-16 | 2023-11-27 | エイビー セラピューティクス インコーポレイテッド | 多重特異性抗体およびその使用方法 |
| KR20230123497A (ko) | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드 |
| IL303783A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| WO2022129637A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| EP4288461A4 (en) | 2021-07-14 | 2025-07-02 | Beijing Ql Biopharmaceutical Co Ltd | FUSION POLYPEPTIDES FOR METABOLIC DISORDERS |
| CN118556077A (zh) * | 2021-11-17 | 2024-08-27 | 南京再明医药有限公司 | 一种多特异性抗体及其药物用途 |
| EP4448574A1 (en) | 2021-12-17 | 2024-10-23 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting tcralphabeta, cd33 and cd123 |
| CN118139892A (zh) * | 2022-01-14 | 2024-06-04 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
| US20240109965A1 (en) | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
| JP2025526384A (ja) | 2022-07-27 | 2025-08-13 | アブリンクス エン．ヴェー． | 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| WO2024131731A1 (zh) | 2022-12-19 | 2024-06-27 | 和铂医药(上海)有限责任公司 | "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用 |
| TW202440614A (zh) | 2022-12-23 | 2024-10-16 | 比利時商艾伯霖克斯公司 | 基於蛋白質的接合載體 |
| AU2024207151A1 (en) | 2023-01-09 | 2025-06-19 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| CN120530125A (zh) * | 2023-01-18 | 2025-08-22 | 北京质肽生物医药科技有限公司 | 融合多肽的液体药物组合物及其使用方法 |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| TW202444757A (zh) | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| TW202446782A (zh) | 2023-04-11 | 2024-12-01 | 美商威特拉公司 | 愛帕琳受體促效劑及其用途 |
| WO2024231348A1 (en) | 2023-05-11 | 2024-11-14 | Vib Vzw | Slc4a4/nbce1 inhibitors |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| TW202515917A (zh) | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| US20250152704A1 (en) | 2023-10-16 | 2025-05-15 | Paragon Therapeutics, Inc. | Fcrn antagonists with improved half-life and methods of use |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| US12459994B2 (en) * | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025217488A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0698097B1 (en) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| NZ540771A (en) | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
| US7476724B2 (en) * | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| CN103254309B (zh) * | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| WO2006129843A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| US7875465B2 (en) | 2005-05-31 | 2011-01-25 | Canon Kabushiki Kaisha | Target substance capturing molecule |
| WO2007085814A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| TW200815470A (en) * | 2006-03-30 | 2008-04-01 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| CA2658612C (en) | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| ATE536369T1 (de) * | 2006-10-11 | 2011-12-15 | Ablynx Nv | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| WO2009042589A1 (en) | 2007-09-24 | 2009-04-02 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| BRPI0907648B1 (pt) | 2008-01-29 | 2022-01-11 | Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine | Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro |
| US9212226B2 (en) | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| DK2285408T3 (en) | 2008-06-05 | 2019-02-04 | Ablynx Nv | AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| WO2010042815A2 (en) | 2008-10-09 | 2010-04-15 | Duke University | Vhh antibody fragments for use in the detection and treatment of cancer |
| EP2346900A1 (en) | 2008-10-29 | 2011-07-27 | Wyeth LLC | Methods for purification of single domain antigen binding molecules |
| UY32514A (es) * | 2009-03-27 | 2010-10-29 | Glaxo Group Ltd | FUSIONES Y CONJUGADOS DE UN FÁRMACO INSULINOTRÓPICO Y dAb CON SEMIVIDA SÉRICAS MEJORADAS |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| MA33930B1 (fr) | 2009-12-18 | 2013-01-02 | Sanofi Sa | Nouveaux anticorps antagonistes contre gpvi et leurs fragments fab et utilisations de ceux-ci |
| WO2011107507A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Biparatopic abeta binding polypeptides |
| RS66008B1 (sr) | 2010-03-10 | 2024-10-31 | Genmab As | Monoklonska antitela protiv c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012042026A1 (en) * | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US20150344568A1 (en) | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| NZ780183A (en) | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723771B1 (en) * | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
-
2012
- 2012-06-14 EP EP12727658.2A patent/EP2723771B1/en active Active
- 2012-06-14 EP EP18205150.8A patent/EP3466972A1/en active Pending
- 2012-06-14 US US14/128,719 patent/US9573992B2/en active Active
- 2012-06-14 WO PCT/EP2012/061304 patent/WO2012175400A1/en not_active Ceased
- 2012-06-14 ES ES12727658T patent/ES2759936T3/es active Active
- 2012-06-14 HU HUE12727658A patent/HUE047238T2/hu unknown
- 2012-06-14 DK DK12727658T patent/DK2723771T3/da active
- 2012-06-14 CN CN201610392570.9A patent/CN106046168A/zh active Pending
- 2012-06-14 HR HRP20192160TT patent/HRP20192160T1/hr unknown
- 2012-06-14 PL PL12727658T patent/PL2723771T3/pl unknown
- 2012-06-14 AU AU2012271974A patent/AU2012271974B2/en active Active
- 2012-06-14 IN IN414CHN2014 patent/IN2014CN00414A/en unknown
- 2012-06-14 EP EP23159592.7A patent/EP4218933A1/en active Pending
- 2012-06-14 LT LT12727658T patent/LT2723771T/lt unknown
- 2012-06-14 JP JP2014516279A patent/JP6324887B2/ja active Active
- 2012-06-14 PT PT127276582T patent/PT2723771T/pt unknown
- 2012-06-14 SI SI201231696T patent/SI2723771T1/sl unknown
- 2012-06-14 CN CN201280030647.8A patent/CN103619878B/zh active Active
- 2012-06-14 CA CA2839779A patent/CA2839779C/en active Active
- 2012-06-25 HR HRP20170535TT patent/HRP20170535T4/hr unknown
-
2017
- 2017-01-03 US US15/397,313 patent/US20170210789A1/en not_active Abandoned
-
2018
- 2018-04-11 JP JP2018076201A patent/JP6843090B2/ja active Active
-
2019
- 2019-12-10 CY CY20191101299T patent/CY1122691T1/el unknown
-
2021
- 2021-02-22 JP JP2021026177A patent/JP7304375B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012271974B2 (en) | 2017-01-12 |
| JP7304375B2 (ja) | 2023-07-06 |
| HRP20170535T1 (hr) | 2017-06-16 |
| PL2723771T3 (pl) | 2020-04-30 |
| PT2723771T (pt) | 2019-12-11 |
| CN103619878B (zh) | 2016-10-26 |
| JP6843090B2 (ja) | 2021-03-17 |
| EP4218933A1 (en) | 2023-08-02 |
| CA2839779C (en) | 2020-10-06 |
| IN2014CN00414A (enExample) | 2015-04-03 |
| JP2018127478A (ja) | 2018-08-16 |
| JP6324887B2 (ja) | 2018-05-16 |
| US20170210789A1 (en) | 2017-07-27 |
| WO2012175400A1 (en) | 2012-12-27 |
| US9573992B2 (en) | 2017-02-21 |
| AU2012271974A1 (en) | 2013-12-12 |
| CY1122691T1 (el) | 2021-03-12 |
| CA2839779A1 (en) | 2012-12-27 |
| EP3466972A1 (en) | 2019-04-10 |
| LT2723771T (lt) | 2019-12-10 |
| EP2723771A1 (en) | 2014-04-30 |
| JP2014520129A (ja) | 2014-08-21 |
| ES2759936T3 (es) | 2020-05-12 |
| DK2723771T3 (da) | 2019-12-02 |
| HRP20192160T1 (hr) | 2020-02-21 |
| HUE047238T2 (hu) | 2020-04-28 |
| HRP20170535T4 (hr) | 2022-08-19 |
| CN103619878A (zh) | 2014-03-05 |
| CN106046168A (zh) | 2016-10-26 |
| US20140228546A1 (en) | 2014-08-14 |
| EP2723771B1 (en) | 2019-09-11 |
| JP2021088585A (ja) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2723771T1 (sl) | Proteini, ki vežejo serum albumin | |
| PL2643349T3 (pl) | Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy | |
| ZA201209091B (en) | Serum albumin binding molecules | |
| EP2681239B8 (en) | Antigen binding proteins | |
| SG11201401649VA (en) | Albumin binding antibodies and binding fragments thereof | |
| ZA201402258B (en) | Cd27l antigen binding proteins | |
| AP2014008053A0 (en) | ST2 antigen binding proteins | |
| ZA201404481B (en) | Il-1 binding proteins | |
| SG2014010334A (en) | Fn14 binding proteins and uses thereof | |
| PL2912054T3 (pl) | Polipeptyd wiążący albuminę | |
| DK2721152T3 (da) | Dimere bindingsproteiner baseret på modificerede ubiquitiner | |
| HRP20181666T1 (hr) | Proteini koji se vežu na antigene, specifični za komponentu p serumskog amiloida | |
| IL226157A0 (en) | Antigen binding proteins | |
| EP2793927A4 (en) | SERUM AMYLOID P ANTIBODY FUSION PROTEIN | |
| HK1177755A (en) | Serum albumin binding molecules |